VC-backed security data provider Rapid7 goes public

Security data and analytics provider Rapid7 has debuted its IPO after pricing its 6.45 million shares at $16 per share. The stock began trading Friday on the NASDAQ under the ticker symbol “RPD.” Morgan Stanley & Co. LLC and Barclays Capital Inc are serving as the lead underwriters. Rapid7 is backed by Bain Capital and Technology Crossover Ventures.


Thoma Bravo ups two to principal

Thoma Bravo has promoted Arvindh Kumar and Chip Virnig to principal. Previously, Kumar and Virnig were vice presidents. Prior to joining Thoma Bravo, Kumar worked at a number of firms that included Prospect Capital Management, BC Partners and Morgan Stanley while Virnig worked in Merrill Lynch & Co’s investment banking group.


PE-owned NEP files for IPO

Pittsburgh-based mobile teleproduction services provider NEP Group Inc has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. The company plans on listing the stock on the New York Stock Exchange under the ticker symbol “NEPG.” Barclays and Morgan Stanley are serving as the lead underwriters. NEP is owned by Crestview Partners.


KKR to sell Capital Safety to 3M

3M has agreed to buy Capital Safety from KKR. The deal is valued at $2.5 billion. Morgan Stanley served as financial advisor to 3M on the transaction while Goldman Sachs was financial advisor to KKR. Based in Bloomington, Minnesota, Capital Safety is a provider of fall proteciton equipment.


PE-backed Patheon files for IPO

Durham, North Carolina-based Patheon, a provider of outsourced pharmaceutical development and manufacturing services, has filed for an IPO. The number of shares that will be sold as well as the stock’s pricing terms have yet to be set. J.P. Morgan, Morgan Stanley, Jefferies and UBS are serving as the lead underwriters. Patheon is owned by JLL Partners and Royal DSM.


J.C. Flowers to buy AmeriLife

J.C. Flowers & Co. LLC has agreed to buy AmeriLife Group from Reservoir Capital Group and Black Diamond Capital Partners. No financial terms were disclosed for the transaction that is expected to close in the second or third quarter of this year. Evercore advised AmeriLife on the transaction while Morgan Stanley & Co. advised J.C. Flowers. AmeriLife is a provider of annuity, life and health insurance products focused on the senior market.


Apollo agrees to buy Protection 1 and ASG Security

Apollo Global Management LLC has agreed to acquire two security monitoring companies Protection 1 and ASG Security. No financial terms were disclosed for the transaction that is expected be completed in mid-2015. Both companies will merge and operate under the Protection 1 brand. Credit Suisse, Barclays, Deutsche Bank, Jefferies and RBC are providing the financing for the deal. Morgan Stanley and Raymond James are providing financial advice to Protection 1 while Goldman Sachs is doing likewise for ASG Security.


PeerIQ expands team with new addition

New York City-based financial information services company PeerIQ has hired Deepak Agnani as head of financial products. Previously, Agnani worked at Markit where he served as head of U.S. indices. PeerIQ is backed by Uprising; John Mack, former chairman and CEO of Morgan Stanley; Vikram Pandit, former Citigroup CEO; Arthur Levitt, former SEC chairman; and Eric Schwartz, former co-CEO of Goldman Sachs Asset Management.


VC-backed Shopify sets IPO pricing terms

Canada-based Shopify Inc, a commerce platform for small and medium-sized businesses, has priced its IPO of 7.7 million shares at between $12 and $14 per share. The company will list the stock on the New York Stock Exchange and the Toronto Stock Exchange under the ticker symbols “SHOP” and “SH” respectively. Morgan Stanley, Credit Suisse and RBC Capital Markets are serving as the lead underwriters. Shopify’s backers include OMERS Ventures, Insight Venture Partners, Bessemer Venture Partners, FirstMark Capital, Georgian Partners and Felicis Ventures.


Intarcia racks up $225 mln

Boston-based biopharmaceutical company Intarcia Therapeutics has raised $225 million in synthetic royalty funding. According to terms of the deal, the investors, who were not named, will have the option to convert their synthetic royalty interests into Intarcia common stock at a $5.5 billion company valuation. Morgan Stanley & Co. LLC served as sole structuring agent to Intarcia on this transaction.

PE HUB Community

Join the 12519 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget